AzTrials
AzTrials

Recurrent Grade 4 GliomaPhase 1CAMPSISNCT07754006

Preliminary Clinical Feasibility Study of a Medical Device Enabling Brain Access Using Microbubble-Enhanced Sonication

A Phase 1 study testing Temporarily and locally induce permeability of the blood-brain barrier (sonication) using TheraOne in people with Recurrent Grade 4 Glioma and Brain Metastases From Extra-cranial Solid Tumors, run by Gustave Roussy, Cancer Campus, Grand Paris at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

CAMPSIS is a preliminary feasibility study of the TheraOne medical device (IIb). TheraOne is an active, non-invasive medical device intended to deliver transcranial FUS in combination with intravenous microbubbles in order to transiently and locally induce the BBB permeability. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Temporarily and locally induce permeability of the blood-brain barrier (sonication) using TheraOne
Could I receive a placebo?
No, everyone receives an active treatment
How many people
6 participants
Where
1 siteFrance
Study dates
Sep 2026to Oct 2027
Phase
Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age: ≥18 years old.
  • Performance Status: Karnofsky Performance Score (KPS) ≥ 70%.
  • Tumor Characteristics:
  • Patient with an expansive intra-cerebral tumor showing enhancement after gadolinium injection on MRI (T1-weighted images, with and without gadolinium contrast).
  • Tumor radiologically classified as:
  • Recurrent High-Grade glioma (excluding prosthetic material), or a brain metastasis from extracranial solid primary.
Show all 51Show fewer
  • Measuring at least 25-30 mm in the longest axis.
  • In both cases, Surgery is not required as a first-line option. However, the target lesion must be considered technically operable (non-eloquent location)
  • In the case of brain metastases, multifocal disease is allowed, provided that additional metastases are smaller to 20 mm, not neurologically threatening, and do not require surgery. Cases of leptomeningeal invasion are not allowed.
  • Tumor should not exhibit signs of rapid progression or acute neurological compromise requiring urgent intervention. Rapid progression is defined as a ≥25% increase in contrast-enhancing tumor volume within 4 weeks, associated with mass effect or new edema. Acute neurological compromise includes any newly developed or worsening neurological deficit (e.g., motor weakness, aphasia), seizures refractory to antiepileptics, decreased level of consciousness (Glasgow Coma Scale (GCS) <13), or signs of intracranial hypertension.
  • Operability and Location:
  • Target Tumor is deemed operable by the neurosurgeon and is located in a non-eloquent area (e.g., excluding brainstem or regions associated with critical motor or speech function).
  • Tumor must be located in the cortical or subcortical regions, at least 20 mm beneath the inner skull surface to ensure accessibility to the TheraOne intervention.
  • In case of brain metastasis, extracerebral disease must be absent or at least controlled, defined as:
  • A Positron Emission Tomography (PET) scan performed within 6 weeks showing resolution of hyperintensity, or
  • Stable disease on two consecutive imaging assessments
  • And oligometastatic state, defined as ≤3 extracerebral lesions.
  • Blood Pressure Stability : Systolic ≤180 mmHg, Diastolic ≤100 mmHg at screening.
  • Coagulation Stability :
  • Platelets ≥80.10 9 /L
  • Prothrombin time (PT) ≤14 sec
  • Partial thromboplastin time (PTT) ≤36 sec
  • International Normalized Ratio (INR) ≤1.3
  • Prior and ongoing treatments
  • Prior systemic anticancer treatments are allowed provided that all the following conditions are met:
  • The patient has a clinically stable neurological status at inclusion.
  • There is no ongoing ≥ Grade 2 neurological toxicity attributable to prior or ongoing systemic treatment.
  • Corticosteroid dose is stable or decreasing for at least 7 days prior to inclusion.
  • The following minimum wash-out periods prior to sonication must be respected:
  • Immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4): ≥ 7 days before sonication.
  • Nitrosourea-containing chemotherapy (BCNU, CCNU): ≥ 6 weeks before sonication.
  • Targeted therapies - lung cancer (EGFR, ALK, ROS1, MET TKIs): Wash-out corresponding to 5 terminal half-lives, capped at a maximum of 7 days, provided neurological stability and absence of recent treatment initiation or dose escalation.
  • Targeted therapies - melanoma (BRAF and/or MEK inhibitors): A short pragmatic wash-out of approximately 5-7 days, not strictly based on pharmacokinetic half-life, may be applied provided neurological status is stable and no ≥ Grade 2 neurological toxicity is present.
  • Anti-angiogenic therapy (bevacizumab):
  • A minimum interval of 7 days prior to sonication is required.
  • Antibody-drug conjugates (ADCs): A wash-out of 7 days prior to sonication is required. ADC treatment must be ongoing (not recently initiated), with no ≥ Grade 2 toxicity, particularly neurological or hematological.
  • Antiplatelet and anticoagulant agents: Must be discontinued according to the following minimum intervals prior to sonication:
  • antiplatelet agents: ≥ 7 days
  • vitamin K antagonists: ≥ 7 days
  • direct oral anticoagulants (NOACs): ≥ 72 hours
  • heparin-derived compounds: ≥ 48 hours
  • Prior brain radiotherapy is allowed provided it was completed ≥ 12 weeks before sonication
  • Renal Function: Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73m².
  • MRI \& CT Compatibility: Patient must be able to complete high-density CT and MRI studies, including contrast-enhanced imaging.
  • Procedure Feasibility :
  • Willingness to undergo partial head shaving to allow proper ultrasound transmission
  • Ability to maintain stable seated position during procedure.
  • Negative Serum Pregnancy Test (within 7 days before first treatment) for women of childbearing potential.
  • Contraceptive Use: Women of childbearing potential and men with partners of childbearing potential must agree to use a highly effective (<1% failure rate per year) approved contraceptive method during procedure and for 6 months post- procedure. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
  • Signed Informed Consent Form.
  • Patients must be affiliated or beneficiary to a social security system

Who cannot join

  • Tumor-Related Exclusions:
  • Tumor imaging features suggestive of:
  • Acute mass effect with ≥5 mm midline shift or basal cistern effacement.
  • Severe peritumoral edema causing acute intracranial hypertension or compression of critical structures.
  • Hemorrhagic transformation or necrosis with a high risk of rupture.
  • Tumor morphology or imaging findings that preclude the ability to sonicate the tumor volume, including:
Show all 75Show fewer
  • Significant tumor volume outside the treatment envelope.
  • Tumor volume exceeding the maximum allowed sonication volume (currently 110 ccs at the treatment volume level).
  • Concerns about adequate tumor coverage by sonication based on tumor morphology should be discussed with the Sponsor.
  • Vascular \& Hemorrhagic Conditions:
  • Cerebrovascular disease history:
  • Untreated arteriovenous malformation (AVM).
  • Untreated or unstable cerebral aneurysm.
  • Acute hemorrhage or cystic lesions:
  • Evidence of acute intracranial hemorrhage.
  • Presence of a cyst within the region of interest (ROI).
  • MRI or clinical findings of:
  • Active or chronic infections/inflammatory processes.
  • Acute or chronic hemorrhages, lobar microbleeds, siderosis, amyloid angiopathy, or macro-hemorrhages.
  • Intracranial thrombosis, vascular malformation, cerebral aneurysm, or vasculitis.
  • Cardiovascular \& Systemic Conditions:
  • Unstable cardiac disease or hemodynamic status.
  • Uncontrolled severe hypertension (systolic >180 mmHg, diastolic >100 mmHg).
  • Anticoagulation \& Bleeding Risks:
  • Use of medications that increase bleeding risk:
  • Antiplatelet agents (e.g., aspirin, clopidogrel) within 7 days prior to treatment.
  • Anticoagulants (e.g., warfarin, dabigatran, apixaban, heparin) within specified washout periods:
  • Oral vitamin K inhibitors: 7 days
  • Non-Vitamin K antagonist oral anticoagulants (NOACs) (e.g., rivaroxaban, apixaban): 72 hours
  • Heparin-derived compounds: 48 hours
  • Abnormal coagulation profile: Platelets <80,000 109/L, PT >14, PTT >36, INR >1.3.
  • History of bleeding disorder, coagulopathy, or spontaneous hemorrhage.
  • Neurological \& Psychiatric Conditions:
  • Active seizures (>1 per week) despite medication, as BBB opening could worsen seizures.
  • Active drug/alcohol disorder, increasing seizure, infection, or compliance risks.
  • Known positive Human Immunodeficiency Virus (HIV) status, which may increase BBB permeability and lead to encephalitis.
  • Potential blood-borne infections that could increase risk of meningitis or brain abscess.
  • Prior treatments incompatible with study participation
  • Any immunotherapy administered within 7 days prior to sonication.
  • Any nitrosourea-containing chemotherapy administered within 6 weeks prior to sonication.
  • Any targeted therapy not meeting the wash-out and stability criteria described above.
  • Any antibody-drug conjugate administered within 7 days prior to sonication or associated with ongoing ≥ Grade 2 toxicity.
  • Any experimental therapy or investigational medicinal product not discontinued ≥ 30 days prior to sonication.
  • Brain radiotherapy completed < 12 weeks prior to sonication
  • Imaging \& Gadolinium Contraindications:
  • Severe claustrophobia or inability to remain supine for 2 hours.
  • Body habitus incompatible with CT or MRI scanner limits
  • Known allergy(ies) or hypersensitivity to gadolinium contrast agents.
  • MRI-incompatible implanted device (e.g., pacemaker, defibrillatore, cochlear implant)
  • Ferromagnetic foreign body
  • Contraindications to Microbubble Use:
  • Hypersensitivity to sulfur hexafluoride microbubbles or any excipient
  • History of severe allergic reactions (anaphylaxis) to contrast agents.
  • Right-to-left cardiac shunt or embolization risk.
  • Severe pulmonary hypertension or unstable cardiac conditions (e.g. unstable ischemic heart disease, acute coronary syndrome within the previous 30 days).
  • Uncontrolled systemic hypertension,
  • Adult respiratory distress syndrome (ARDS)
  • Any SmPC-listed contraindication
  • Contraindications/ constraints from associated non-experimental devices :
  • Ultrasound gel :
  • Known hypersensitivity to any component of the ultrasound gel used during the procedure
  • Cervical collar (PATRIOT) , contraindications per IFU
  • Compromised airway,
  • Known severe spinal deformity (e.g., ankylosing spondylitis),
  • Penetrating trauma injuries (cervical).
  • Positionning chair :
  • Inability to maintain a stable seated position for the duration of the procedure.
  • Other Procedure-Related Exclusions:
  • Presence of metallic implants (e.g., clips in skull/brain) interfering with sonication.
  • Scalp infection at target site
  • Psychological, Social \& Legal Factors:
  • Mental health disorders or social/geographical barriers that could affect CI compliance.
  • Patients under legal protection, guardianship, or deprived of liberty.
  • Pregnancy \& Breastfeeding:
  • Pregnant or breastfeeding women, or those planning pregnancy during the CI and 6 months after.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sophie Bockel, MD, PhD contact

+33 (0)1 42 11 42 11

sophie.bockel@gustaveroussy.fr

Ophélie Lion contact

+33 (0)1 42 11 48 41

ophelie.lion@gustaveroussy.fr

France1 site

  • Gustave Roussy

    Villejuif, France, 94800

    Sophie Bockel, MD, PhD, +33 (0)1 42 11 42 11, sophie.bockel@gustaveroussy.fr

Other trials in France

About this study

Official title: Cerebral Access Using Microbubble Potentiated Sonication: Initial Study

CAMPSIS is a preliminary feasibility study of the TheraOne medical device (IIb). TheraOne is an active, non-invasive medical device intended to deliver transcranial FUS in combination with intravenous microbubbles in order to transiently and locally induce the BBB permeability.

This study aims to evaluate the safety of cerebral sonication (TheraOne) in the management of patients with recurrent grade 4 glioma (wild-type IDH, technically resectable) or brain metastases originating from an extracranial solid tumor.

Read more

Patients enrolled in the study will undergo a single sonication session during a protocol visit and will be monitored for up to 30 days after the sonication through the various scheduled protocol visits.

Blood samples will be collected at the start of the study, during the sonication, and during the post-sonication follow-up visit for all patients enrolled in the study.

Being tested
Temporarily and locally induce permeability of the blood-brain barrier (sonication) using TheraOne

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Temporarily and locally induce permeability of the blood-brain barrier (sonication) using TheraOneProcedure or surgery

    TheraOne is an active, non-invasive medical device intended to deliver transcranial FUS in combination with intravenous microbubbles in order to transiently and locally induce the BBB permeability.

Study groups in NCT07754006
Study groupRoleWhat they receive
Patients with recurrent grade 4 glioma or brain metastasis from an extracranial solid tumorExperimentalNot described
Receives: Procedure: Temporarily and locally induce permeability of the blood-brain barrier (sonication) using TheraOne

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety : evaluating the occurrence and severity of adverse events related to the sonication procedure

    Measured: Up to 14 days after the sonication

Secondary outcomes (2)

  1. Feasibility : completion rate of sonication phase

    Measured: Immediately after the procedure.

  2. BBB permeability assessment by several MRI imaging at predefined timepoints.

    Measured: Up to 14 days after the sonication

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Aug 2026
  2. Study startSep 2026 (estimated)
  3. Primary completionSep 2027 (estimated)
  4. Study completionOct 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
6 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07754006
Sponsor's protocol ID
2025-A02389-40
Other IDs
2026/4280
Acronym
CAMPSIS
Status last verified
Jul 2026
First submitted
3 Aug 2026
Last updated
10 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Temporarily and locally induce permeability of the blood-brain barrier (sonication) using TheraOne in people with Recurrent Grade 4 Glioma and Brain Metastases From Extra-cranial Solid Tumors, run by Gustave Roussy, Cancer Campus, Grand Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 51 inclusion and 75 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sophie Bockel, MD, PhD (+33 (0)1 42 11 42 11, sophie.bockel@gustaveroussy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety : evaluating the occurrence and severity of adverse events related to the sonication procedure (time frame: Up to 14 days after the sonication). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07754006.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in